

CTS GUIDELINES RECOMMEND PRN BUDESONIDE/FORMOTEROL AS A RELIEVER OPTION FOR ADULTS AND CHILDREN ≥ 12 YEARS OF AGE¹

- PRN budesonide/formoterol is a recommended option for individuals with **mild asthma** not controlled on PRN SABA who have poor adherence to daily ICS despite substantial asthma education and support.¹
- PRN budesonide/formoterol in combination with low-moderate dose budesonide/formoterol maintenance therapy can be an option for individuals with **moderate asthma**.¹

SYMBICORT® TURBUHALER® (budesonide and formoterol fumarate dihydrate) is indicated for the treatment of asthma in patients 12 years and older with reversible obstructive airways disease.²

CHOOSE SYMBICORT TURBUHALER FOR YOUR PATIENTS WITH ASTHMA.



CTS: Canadian Thoracic Society; ICS: inhaled corticosteroids.

Pr **Symbicort**®
budesonide/formoterol
fumarate dihydrate

SYMBICORT TURBUHALER. THE #1 DISPENSED ICS/LABA.³

Clinical use:

SYMBICORT TURBUHALER can be used according to three different treatment approaches:

- A. SYMBICORT TURBUHALER Anti-Inflammatory Reliever Therapy:** in patients with mild persistent asthma, SYMBICORT 200 TURBUHALER is taken as needed for relief of asthma symptoms when they occur. SYMBICORT TURBUHALER has not been evaluated in patients whose asthma can be managed by occasional use of a rapid-onset, short-duration, inhaled beta₂-agonist.
- B. SYMBICORT TURBUHALER Anti-Inflammatory Reliever plus Maintenance Therapy:** in patients with moderate or severe asthma, SYMBICORT 100 TURBUHALER or SYMBICORT 200 TURBUHALER are taken both as daily maintenance therapy and as needed for relief of asthma symptoms when they occur.
- C. SYMBICORT TURBUHALER Maintenance Therapy:** in patients with moderate or severe asthma, SYMBICORT TURBUHALER is taken as a fixed-dose daily treatment with a separate short-acting bronchodilator for relief of symptoms when they occur.

Once asthma control is achieved and maintained, the patient should be assessed at regular intervals.

Contraindications:

Hypersensitivity to inhaled lactose.

Most serious warnings and precautions:

Risk of serious asthma-related events — hospitalizations, intubations, and death: Use of long-acting beta₂-agonists (LABA) as monotherapy (without inhaled corticosteroids [ICS]) will increase the risk of asthma-related death and the risk of asthma-related hospitalizations in pediatric and adolescent patients. These findings are considered a class effect of LABA monotherapy. When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone.

Asthma reliever medication: Inform patients to have reliever medication available at all times. Asthma patients should be clearly instructed to use medication for relief of asthma symptoms (e.g., SYMBICORT TURBUHALER, terbutaline, or salbutamol).

Excessive use and use with other LABA products: Do not exceed the prescribed SYMBICORT TURBUHALER dose. Cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.

ICS: inhaled corticosteroids; LABA: long-acting beta₂-agonists.

- References:** 1. Yang CL, et al. Canadian Thoracic Society 2021 Guideline update: Diagnosis and management of asthma in preschoolers, children and adults. *Can J Respir Crit Care Sleep Med.* 2021; 5(6):348–361.
2. Symbicort® Turbuhaler® Product Monograph. AstraZeneca Canada Inc. February 8, 2021.
3. Data on file. AstraZeneca Canada Inc. April 15, 2024.

Use in adolescents: Periodic reassessment should be considered as severity of asthma may vary with age. Possible systemic effects, which may occur with any inhaled corticosteroid, include growth retardation in children and adolescents. Physicians should closely follow the growth of adolescents taking long-term corticosteroids and weigh the benefits of asthma control against the possible risk of growth suppression.

Systemic effects of corticosteroids: May occur with any inhaled corticosteroid and include Cushing's syndrome, Cushingoid features and adrenal suppression, decrease in bone mineral density, cataract, and glaucoma. Any inhaled corticosteroid should be titrated to the lowest dose at which effective control is maintained.

Treatment cessation: Maintenance treatment with ICS should not be stopped abruptly but tapered gradually under supervision.

Other relevant warnings and precautions:

- Cardiovascular effects
- Candidiasis
- Hyperglycemia, hypokalemia
- Enhanced effect of corticosteroids on patients with hypothyroidism and cirrhosis
- Adrenal insufficiency in patients transferred from systemic steroid
- Decreased bone mineral density
- In rare cases, systemic eosinophilic conditions
- Susceptibility or decreased resistance to infection
- Glaucoma, increased intraocular pressure and cataracts
- Paradoxical bronchospasm
- Potential risk during pregnancy, labour, delivery or nursing
- Not recommended in patients <12 years of age
- Special caution in patients >65 years of age with concomitant cardiovascular disease
- Control of asthma should be monitored
- HPA-axis function and hematological status should be assessed periodically

For more information:

Consult the [Product Monograph](#) for important information regarding adverse reactions, drug interactions, and dosing. The Product Monograph is also available by calling AstraZeneca Canada at **1-800-668-6000**.

SYMBICORT®, TURBUHALER® and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc.

© AstraZeneca Canada Inc. 2024
1004 Middlelegate Road, Suite 5000, Mississauga, Ontario, L4Y 1M4
CA-7072E



AstraZeneca